XML 35 R25.htm IDEA: XBRL DOCUMENT v3.25.3
Revision of Previously Issued Financial Statements
 9 Months Ended
Sep. 30, 2025
Accounting Changes and Error Corrections [Abstract]  
Revision of Previously Issued Financial Statements REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS
In preparing the Consolidated Financial Statements as of and for the three and nine months ended September 30, 2025, Management identified certain income tax-related adjustments that primarily relate to the understatement of income tax expense due to errors in the accounting for transfer pricing, the correction of deferred tax liabilities on goodwill recorded in purchase accounting, and other income tax entries that impacted prior interim and annual financial statements.
Management assessed the materiality of the errors on prior period interim and annual consolidated financial statements in accordance with the Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin No. 99, “Materiality,” codified in ASC 250, Accounting Changes and Error Corrections (“ASC 250”). Based on this assessment, in consideration of both quantitative and qualitative factors, we determined that the related impacts were not material to any previously issued interim or annual financial statements. However, if the corrections were recorded in the three months ended September 30, 2025, they would be material to that period. As such, we revised the previously issued consolidated financial statements for the three and nine months ended September 30, 2024 to correct for the errors in this Form 10-Q. The Company will also correct previously issued financial information for these errors that is not included in this Form 10-Q in its future Quarterly Reports to be filed on Form 10-Q and future Annual Reports to be filed on Form 10-K, as applicable. In conjunction with the revision, we also corrected certain other errors that were previously identified and concluded to be immaterial, individually and in the aggregate, to the Company’s consolidated financial statements as of and for the relevant periods. These include an adjustment to the Pharma Solutions disposal group loss on business disposal which should have been recognized upon the initial classification of the disposal group as held for sale, tax adjustments identified in prior periods primarily related to deferred taxes, balance sheet misclassifications to correct the netting of value added tax receivables and payables and uncertain tax provisions and benefits, an error in the classification of uncertain tax provisions recognized as deferred tax liabilities, an adjustment to record the right of use asset and lease liability related to a lease upon lease commencement that was incorrectly omitted, and a cash flow adjustment to correct the classification of cash paid/received on foreign currency forward contracts from operating activities to investing activities. The applicable notes to the accompanying Consolidated Financial Statements have also been revised to reflect the correction of the errors.
The Company also revised the Inventory and Property, plant, and equipment, net disclosures as of December 31, 2024 revising Raw materials from $657 million to $627 million and Finished goods from $1,108 million to $1,138 million, Land from $136 million to $137 million, Building and improvements from $1,688 million to $1,690 million, Machinery and equipment from $3,447 million to $3,466 million, Information technology from $507 million to $514 million, and Construction in process from $389 million to $360 million to correct the timing of transfer of completed Construction in process projects into service. There was no change to the total Inventory or Property, plant, and equipment, net.
The following tables reflect the impact of the revision to the specific line items presented in our previously reported financial information for the periods impacted by the revision. The Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) and the Consolidated Statements of Cash Flows for the three months ended March 31, 2025 are not presented as the period was not impacted by the revision.
Impacts to Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)
Year Ended December 31, 2024Year Ended December 31, 2023
(DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS)As ReportedAdjustmentsAs RevisedAs ReportedAdjustmentsAs Revised
Loss on assets classified as held for sale$347 $(30)$317 $— $— $— 
Income (loss) before income taxes278 30 308 (2,518)— (2,518)
Provision for income taxes31 10 41 45 24 69 
Net income (loss)247 20 267 (2,563)(24)(2,587)
Net income (loss) attributable to IFF shareholders243 20 263 (2,567)(24)(2,591)
Net income (loss) per share - basic$0.95 $0.09 $1.04 $(10.05)$(0.09)$(10.14)
Net income (loss) per share - diluted$0.95 $0.09 $1.04 $(10.05)$(0.09)$(10.14)
Comprehensive income (loss)(384)20 (364)(2,261)(24)(2,285)
Comprehensive income (loss) attributable to IFF shareholders $(388)$20 $(368)$(2,265)$(24)$(2,289)
Six Months Ended June 30, 2025Three Months Ended June 30, 2025
(DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS)As ReportedAdjustmentsAs RevisedAs ReportedAdjustmentsAs Revised
Loss on Business Disposals$81 $30 $111 $81 $30 $111 
Income (loss) before income taxes(460)(30)(490)534 (30)504 
(Benefit) for income taxes(55)(4)(59)(78)(4)(82)
Net income (loss)(405)(26)(431)612 (26)586 
Net income (loss) attributable to IFF shareholders(406)(26)(432)612 (26)586 
Net income (loss) per share - basic$(1.59)$(0.10)$(1.69)$2.39 $(0.10)$2.29 
Net income (loss) per share - diluted$(1.59)$(0.10)$(1.69)$2.38 $(0.10)$2.28 
Comprehensive income (loss)707 (26)681 1,320 (26)1,294 
Comprehensive income (loss) attributable to IFF shareholders $706 $(26)$680 $1,320 $(26)$1,294 
Three Months Ended December 31, 2024Nine Months Ended September 30, 2024
(DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS)As ReportedAdjustmentsAs RevisedAs ReportedAdjustmentsAs Revised
Loss on assets classified as held for sale$33 $— $33 $314 $(30)$284 
Income (loss) before income taxes(115)— (115)393 30 423 
Provision (benefit) for income taxes(69)14 (55)100 (4)96 
Net income (loss)(46)(14)(60)293 34 327 
Net income (loss) attributable to IFF shareholders(46)(14)(60)289 34 323 
Net income (loss) per share - basic$(0.18)$(0.05)$(0.23)$1.13 $0.14 $1.27 
Net income (loss) per share - diluted$(0.18)$(0.05)$(0.23)$1.13 $0.14 $1.27 
Comprehensive income (loss)(813)(14)(827)429 34 463 
Comprehensive income (loss) attributable to IFF shareholders $(813)$(14)$(827)$425 $34 $459 
Three Months Ended September 30, 2024Six Months Ended June 30, 2024
(DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS)As ReportedAdjustmentsAs RevisedAs ReportedAdjustmentsAs Revised
Loss on assets classified as held for sale$32 $— $32 $282 $(30)$252 
Income (loss) before income taxes95 — 95 298 30 328 
Provision (benefit) for income taxes35 1 36 65 (5)60 
Net income (loss)60 (1)59 233 35 268 
Net income (loss) attributable to IFF shareholders59 (1)58 230 35 265 
Net income (loss) per share - basic$0.23 $— $0.23 $0.90 $0.14 $1.04 
Net income (loss) per share - diluted$0.23 $— $0.23 $0.90 $0.14 $1.04 
Comprehensive income (loss)615 (1)614 (186)35 (151)
Comprehensive income (loss) attributable to IFF shareholders $614 $(1)$613 $(189)$35 $(154)
Three Months Ended June 30, 2024Three Months Ended March 31, 2024
(DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS)As ReportedAdjustmentsAs RevisedAs ReportedAdjustmentsAs Revised
Loss on assets classified as held for sale$282 $(30)$252 $— $— $— 
Income (loss) before income taxes183 30 213 115 — 115 
Provision (benefit) for income taxes11 6 17 54 (11)43 
Net income (loss)172 24 196 61 11 72 
Net income (loss) attributable to IFF shareholders170 24 194 60 11 71 
Net income (loss) per share - basic$0.67 $0.09 $0.76 $0.23 $0.05 $0.28 
Net income (loss) per share - diluted$0.66 $0.10 $0.76 $0.23 $0.05 $0.28 
Comprehensive income (loss)48 24 72 (234)11 (223)
Comprehensive income (loss) attributable to IFF shareholders $46 $24 $70 $(235)$11 $(224)
Impacts to Consolidated Balance Sheets
December 31, 2024December 31, 2023
(DOLLARS IN MILLIONS)As ReportedAdjustmentsAs RevisedAs ReportedAdjustmentsAs Revised
Assets held for sale$3,030 $26 $3,056 $506 $— $506 
Prepaid expenses and other current assets737 (51)686 875 (8)867 
Total Current Assets7,993 (25)7,968 6,293 (8)6,285 
Goodwill9,080 (5)9,075 10,635 (9)10,626 
Operating lease right-of-use assets573 16 589 689 — 689 
Other Assets837 70 907 764 50 814 
Total Assets28,667 56 28,723 30,978 33 31,011 
Other current liabilities783 19 802 977 11 988 
Total Current Liabilities4,333 19 4,352 3,758 11 3,769 
Deferred income taxes1,592 2 1,594 1,937 (7)1,930 
Operating lease liabilities534 16 550 642 — 642 
Other Liabilities566 61 627 560 91 651 
Total Other Liabilities10,423 79 10,502 12,578 84 12,662 
Accumulated deficit(2,605)(42)(2,647)(2,439)(62)(2,501)
Total Shareholders’ Equity13,876 (42)13,834 14,611 (62)14,549 
Total Shareholders’ Equity including Non-controlling interests13,911 (42)13,869 14,642 (62)14,580 
Total Liabilities and Shareholders’ Equity$28,667 $56 $28,723 $30,978 $33 $31,011 
Impacts to Consolidated Statements of Shareholders’ Equity
As ReportedAdjustmentsAs Revised
(DOLLARS IN MILLIONS)Retained Earnings (Accumulated Deficit)TotalRetained Earnings (Accumulated Deficit)Retained Earnings (Accumulated Deficit)Total
Balance at January 1, 2023$955 $17,685 $(38)$917 $17,647 
Net income (loss)(2,567)(2,563)(24)(2,591)(2,587)
Balance at December 31, 2023(2,439)14,642 (62)(2,501)14,580 
Balance at January 1, 2024(2,439)14,642 (62)(2,501)14,580 
Net income (loss)243 247 20 263 267 
Balance at December 31, 2024$(2,605)$13,911 $(42)$(2,647)$13,869 
The Company’s Consolidated Statements of Shareholders’ Equity for the interim periods were also affected by the revised retained earnings (accumulated deficit) amounts for the periods presented above.
Impacts to Consolidated Statements of Cash Flows
Year Ended December 31, 2024Year Ended December 31, 2023
(DOLLARS IN MILLIONS)As ReportedAdjustmentsAs RevisedAs ReportedAdjustmentsAs Revised
Net Income (loss)$247 $20 $267 $(2,563)$(24)$(2,587)
Adjustments to reconcile to net cash provided by operating activities:
Deferred Income taxes(304)(19)(323)(369)(2)(371)
Loss on assets classified as held for sale347 (30)317 — — — 
Changes in assets and liabilities, net of acquisitions:
Other assets/liabilities, net(94)29 (65)(102)42 (60)
Net cash provided by operating activities $1,070 $— $1,070 $1,439 $16 $1,455 
Cash received (paid) on foreign currency forward contracts(102)— (102)— (16)(16)
Net cash provided by investing activities $326 $— $326 $574 $(16)$558 
Six Months Ended June 30, 2025Nine Months Ended September 30, 2024
(DOLLARS IN MILLIONS)As ReportedAdjustmentsAs RevisedAs ReportedAdjustmentsAs Revised
Net Income (loss)$(405)$(26)$(431)$293 $34 $327 
Adjustments to reconcile to net cash provided by operating activities:
Deferred Income taxes(163)(1)(164)(128)(15)(143)
Loss on assets classified as held for sale— — — 314 (30)284 
Loss on business disposals8130111— — — 
Changes in assets and liabilities, net of acquisitions:
Other assets/liabilities, net26 (3)23 (102)(10)(112)
Net cash provided by operating activities $368 $— $368 $702 $(21)$681 
Cash received (paid) on foreign currency forward contracts112 — 112 — 21 21 
Net cash provided by investing activities $2,541 $— $2,541 $586 $21 $607